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Abstract
Background: The concept of frailty is rapidly gaining attention as an independent syndrome with high prevalence
in older adults. Thereby, frailty is often related to certain adverse outcomes like mortality or disability. Another
adverse outcome discussed is increased health care utilization. However, only few studies examined the impact of
frailty on health care utilization and corresponding costs. The aim of this study was therefore to investigate
comprehensively the relationship between frailty, health care utilization and costs.
Methods: Cross sectional data from 2598 older participants (57–84 years) recruited in the Saarland, Germany,
between 2008 and 2010 was used. Participants passed geriatric assessments that included Fried’s five frailty criteria:
weakness, slowness, exhaustion, unintentional weight loss, and physical inactivity. Health care utilization was
recorded in the sectors of inpatient treatment, outpatient treatment, pharmaceuticals, and nursing care.
Results: Prevalence of frailty (≥3 symptoms) was 8.0 %. Mean total 3-month costs of frail participants were €3659
(4 or 5 symptoms) and €1616 (3 symptoms) as compared to €642 of nonfrail participants (no symptom). Controlling for
comorbidity and general socio-demographic characteristics in multiple regression models, the difference in total costs
between frail and non-frail participants still amounted to €1917; p < .05 (4 or 5 symptoms) and €680; p < .05 (3 symptoms).
Among the 5 symptoms of frailty, weight loss and exhaustion were significantly associated with total costs after
controlling for comorbidity.
Conclusions: The study provides evidence that frailty is associated with increased health care costs. The analyses
furthermore indicate that frailty is an important factor for health care costs independent from pure age and comorbidity.
Costs were rather attributable to frailty (and comorbidity) than to age. This stresses that the overlapping concepts of
multimorbidity and frailty are both necessary to explain health care use and corresponding costs among older adults.
Keywords: Economic, Utilization of services, Frailty, Costs, Old age
Background
Life expectancy increases substantially in virtually all de-
veloped countries [1], leading to a larger number of older
people living in these countries. Old age is accompanied
by many geriatric phenomena that include, for example,
multiple chronic conditions, also referred to as ‘multimor-
bidity’ [2, 3]. As the number of people in old age increases,
many studies investigated the impact of multimorbidity
on health care costs [4]. These studies find in general a
positive association of multimorbidity and health care
costs, stressing the importance of this phenomenon for
the health care system.
Another medical phenomenon associated with age is
people’s vulnerability to negative health outcomes and the
general loss of resources. This phenomenon of frailty has
increasingly received attention during the past decades.
Thus, it has been shown that frailty is frequent in old age
[5], and the number of frail people is expected to rise rap-
idly due to demographic change, stressing its importance
for health care systems.
Despite the great attention in the gerontological field,
there is no generally accepted definition of frailty [6–8].* Correspondence: j.bock@uke.de
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Fried et al. proposed a definition of frailty that character-
izes it as an independent phenotype differing from comor-
bidity and disability [9]. According to their definition,
frailty is a clinical syndrome constituted by the co-
occurrence of at least three of the following five criteria:
unintentional weight loss, exhaustion, weakness, slow
walking speed, and low physical activity. Fried et al. [9] as
well as other studies [10] related frailty to certain ‘adverse
outcomes’, for which the predictive validity of frailty has
been investigated. For example, frailty has been found to
be highly predictive for mortality [11–14]. Another
adverse outcome potentially associated with frailty is in-
creased health care utilization. Some studies examined the
relationship between frailty and health care utilization,
finding in particular an increased hospitalization rate
among frail older adults [9, 15–21].
In order to extend these studies and provide evidence
from a representative large population-based sample, we
aimed at examining comprehensively the effect of frailty
on health care utilization and corresponding costs in all
important health care sectors, including inpatient services,
outpatient services, pharmaceuticals, and nursing care.
Thus, it was our goal to present cost estimates for frailty.
In particular, the aims of this study were i) to investigate
the relationship between frailty and health care costs in a
large sample of older adults and ii) to determine the re-
spective associations of the different frailty criteria and
health care costs.
Methods
Sample
The cross-sectional analyses presented in this manuscript
are based on the 8-year follow-up wave of the “Epidemio-
logical investigations on chances of preventing, recognizing
early and optimally treating chronic diseases in an elderly
population”, the ESTHER-Study. ESTHER is a large pro-
spective observational cohort study of older Germans. For
this study, 9949 patients, aged 50–75 years, were recruited
via their GPs in the Saarland, Germany between July 2000
and December 2002. Participants’ socio-demographic and
lifestyle factors were collected by standardized question-
naires and clinical data by their general practitioners (GPs)
and study physicians. Follow-up questionnaires were sent
to the participants and their GPs 2, 5 and 8 years after
recruitment. From baseline-recruitment to the 8-year
follow-up, 1033 participants had died, 1904 had discontin-
ued further active participation, thereof 253 for health rea-
sons. The questionnaire of the 8-year follow-up was
provided either by the GPs or by the patient for 7012 study
participants. This corresponds to an 80.9 % response rate
among survivors still mentally and physically able to re-
spond. Information from both the GP’s and the patient’s
questionnaires was collected for 5057 of the participants.
At the 8-year follow-up, participants were invited in
written form by the study secretariat to take part in de-
tailed geriatric assessments that were conducted at the par-
ticipants’ homes by trained study doctors. Participation
was optional and reasons for denying participation were
not collected. For the geriatric assessments several data
were collected, e.g. on (instrumental) activities of daily liv-
ing, body weight, height, cognitive abilities, measures and
constitution. Moreover, the assessments included inter-
views to collect the health service use as well as measure-
ment of frailty symptoms to be used for the analysis
in the present study. 3124 study participants in whom
home visits were completed accepted the additional offer.
Further detailed information about ESTHER can be found
elsewhere [14, 22–25]. All following analyses were based
on the subsample of the 8-year follow-up with compre-
hensive geriatric assessment at the home visits and for
whom data provided by the GP were available (n = 2598
participants). Figure 1 shows the sample selection process.
Ethics, consent and permission
The ESTHER study has been approved by the ethics
committees of the Medical Faculty of the University of
Heidelberg and the Medical Association of Saarland. A
signed statement of informed consent has been obtained
from all participants included in the ESTHER study.
Health care costs
As recommended [26], we adopted a societal perspective
for calculating health care costs. The calculation of health
care costs generally contains three steps [27]: 1) Identify-
ing relevant cost components; 2) collecting resource con-
sumption for these identified components; 3) valuing the
resource consumption. For the first step, we considered
the following health care sectors as highly relevant for the
cost calculation: inpatient treatment, outpatient treatment
including physician and non-physician outpatient treat-
ment, medical supplies, dental prostheses, pharmaceuti-
cals, and nursing care, the latter including both formal
and informal care.
For the second step, data on the resource consumption
was collected retrospectively for a 3-month period using a
previously developed and tested questionnaire [28, 29].
The questionnaire comprehensively listed health care
goods and services that older adults could potentially use
in order to minimize recall bias; it is available as Additional
file 1. Cognitive abilities of participants were on average
very good as indicated by a mean MMSE [30] of 28.2
points (SD: 2.1). Only 5.3 % of participants scored less than
25 points and can thus be classified as at least mildly cog-
nitively impaired. This suggests that the recall period of
3 month was appropriate at least for the vast majority of
participants. The questionnaire was handed over to and
filled out by the participant during the geriatric assess-
ments at his or her home. For the inpatient sector, the
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questionnaire recorded the number of days in hospital.
Outpatient medical services were measured in terms of
physician visits; medical supplies, such as walkers, hearing
aids etc., in terms of their respective quantities. Pharma-
ceuticals were directly recorded by means of barcode
readers by the study physicians. Nursing care included pro-
fessional home care in terms of hours, and nursing home
care in terms of days in institutionalized homes. The use of
informal care was recorded by asking participants, i.e. the
potential receivers of informal care, whether they utilized
aid for reasons of high age or bad health provided by
spouses, other family members, friends or neighbors. The
analyses did not consider indirect costs. A majority of the
participants had already reached the retirement age, for the
remaining ones, we focused on direct health care costs.
The third step contained the monetary valuation of the
quantities of the resource used with corresponding unit
costs for inpatient care [31–33], outpatient care [34–38],
medical devices [34, 39, 40], pharmaceuticals [41], nursing
home care [42], professional home care and informal care
[43, 44]. The costing process is depicted in Table 1. Fur-
ther details concerning the costing for the 8-year follow-
up-wave of ESTHER have also been reported in detail
elsewhere [45]. Costs were calculated based on prices of
the year 2009.
Frailty
We create a frailty index according to Fried et al. [9] based
on the five criteria: weakness, slowness, exhaustion, weight
loss, and physical inactivity. The index was created by
assigning a score of one if one of the five criteria was met,
two if two of the five were met, etc. Persons with one or
two criteria fulfilled were referred to as ‘pre-frail’, those
with at least three as ‘frail’. Trained study physicians mea-
sured the symptoms at participants’ homes. We opera-
tionalized the five criteria as described elsewhere in detail
[23]. Weakness was measured as grip strength, assessed
three times by use of a Jamar hand dynamometer. For the
analyses, the best result of the three measurements was
used. Slowness was measured using the Short Physical
Performance Battery (SPPB) [46]. The average walking
distance per second in m/s was derived from the time to
walk 3 m. Exhaustion was measured based on two ques-
tions [9] of the Center for Epidemiologic Studies Depres-
sion Scale (CES-D) [47]: “I felt that everything I did was
an effort” and “I could not get going”. Weight loss was op-
erationalized as an unintentional loss of at least 5 kg dur-
ing the last year. Physical activities were assessed by
means of the Physical Activity Questionnaire for the
Elderly (PAQE) [48]. In contrast to Fried et al., we used
population-independent cut-off points for the individual
frailty criteria [23] in order to provide results that are
comparable to other samples.
Comorbidity
In order to calculate the net impact of frailty on health
care costs, i.e. the impact irrespective of the potential
influence of chronic conditions, cost estimates were
adjusted for the influence of comorbidity. As measure of
comorbidity, we considered the Cumulative Illness
Fig. 1 Flow chart of sample selection in follow-up 8 of the ESTHER study
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Rating Scale for Geriatrics (CIRS-G) [49, 50]. The CIRS-
G is a generic measure of comorbidity consisting of 13
somatic categories and one psychiatric category. Each
category is weighted according to severity by the GP
with 0 points (‘no problem’) to 4 points (‘very severe
problems’). The sum score over each category’s points
defines the CIRS-G that can range from 0 to 56.
Other variables
The statistical models include the covariates age, sex,
marital status, educational level and type of health insur-
ance. Marital status distinguished between single, mar-
ried, divorced, and widowed. The educational level was
operationalized as duration of primary and secondary
school education, consisting of three classes: ≤9 years,
10–11 years, and ≥12 years. Participants’ type of health
insurance could vary between statutory health insurance
and private health insurance, reflecting the dualistic sys-
tem of health insurance in Germany. While the majority
of about 90 % of the overall German population are a
members of a Statutory Health Insurance (SHI), the
remaining 10 % are privately insured. Mandatory mem-
bers of a SHI are especially employees under an income-
threshold and, in general, their spouses and children.
Both types of health insurance offer comprehensive
coverage of costs in the inpatient and outpatient phys-
ician setting, and of prescription drugs. Moreover, per-
manent nursing care (both ambulatory and in nursing
homes) is partially reimbursed by compulsory long-term
care insurances.
Statistical analyses
All statistical analyses were done using Stata Release 14.
The relationship between frailty as well as the single
frailty symptoms and health care costs was analyzed
using generalized linear models (glm) with log link func-
tion and gamma distribution, a commonly used type of
model for skewed cost data [51]. For the health care sec-
tors of inpatient treatment and nursing care, there was a
vast majority of participants not using any services in
these sectors during the 3 months preceding the inter-
views. This results in distributions of sectoral costs with
many zero values, while the cost data of the users were
positively skewed. Therefore, we calculated two-part
models [52, 53], with the first part specified as ‘logit’, and
the second part as glm with log link function and
gamma distribution. For both total and sectoral regres-
sion models, we present the marginal effects at means of
all variables obtained from the ‘twopm’ command [54],
which can be interpreted in the same metric as the
dependent variable, i.e. 3-month health care costs.
In order to examine robustness of regression models,
the possible effect of frailty on sectoral and total health
care costs was also investigated using multiple Tobit
regression models. The characteristics of our dependent
variables, in particular inpatient and nursing care cost
Table 1 Recorded resource utilization and source of valuation (Adapted from [45])
Health care sector Example of resources Unit Soource
In-patient treatment Stays in general hospitals, specialized psychiatric
and neurological hospitals or rehabilitation clinics
(including day patient treatment)
Days in
hospital
Calculated costs of care per day by type (Federal
Statistical Office, German Hospital Federation,
Statutory Pension Insurance Fund) [31–33]
Out-patient physician
treatment
Treatment by GPs, specialists and out-patient clinics Number
of visits
Calculated costs per contact, by specialization [34]
Other out-patient
treatment
E.g. physiotherapy, massage, occupational therapy,
non-medical practitioner
Number
of visits
Reimbursement schedules (Statutory health insurance
funds; [35–37], calculated costs per contact [34], by type,
schedule of fees (Federal office of administration) [38]
Medical supplies and
dental prostheses
E.g. walkers, incontinence pads, hearing aids,
surgical stockings, dental bridge, crown
Quantity Reimbursement schedules (Statutory health insurance
funds, Federal Association of Panel Dentists; [39, 40],
calculated costs per item [34], by type
Pharmaceuticals Specific products (including trade name, drug
code, package size, pharmaceutical form, dosage)
Quantity Pharmacy retail prices (MMI-Pharmindex, Medizinverlag
Medizinische Medien Informations GmbH (MMI,
Neu-Isenburg) [41]
Nursing home care Nursing home stays (residential and day care) Days Calculated costs of care per day (Federal Statistical Office)
[42], by type
Professional
home care
Care and assistance provided by professional
nursing services and other paid help, differentiated
by type (e.g. basic care, assistance with cleaning,
shopping, financial matters etc.) and limited to
care or assistance required owing to illness or age
Hours Hourly gross wage rate plus non-wage labor costs for
employees in the domain of care and assistance for the
elderly or handicapped (Federal Statistical Office) [43, 44]
Informal care Care and assistance provided by family or friends,
differentiated by type and limited to care or assistance
required owing to illness or age
Hours Replacement cost method: Hourly gross wage rate plus
non-wage labor costs for employees in the domain of
care and assistance for the elderly or handicapped
(Federal Statistical Office) [43, 44]
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with many zero values, were similar to those of censored
data, for which Tobit models are recommended [55].
All regression analyses were performed with and with-
out including the comorbidity status, operationalized as
the CIRS-G. Thus, regression analyses firstly show the
results of excess costs associated with frailty irrespective
of morbidity status. Then, adjusting for morbidity status,
they show the net excess costs associated with frailty
with constant comorbidity. These models were run sep-
arately since frailty and comorbidity are overlapping
concepts [19] with unclear causal interferences. The cor-
relation between the frailty index and CIRS-G was 0.3.
We performed complete case analyses (listwise deletion)
because missing values in any variable occurred in only 90
out of 2598 observations (3.5 %). The level of significance
was set to α = 0.05.
Results
Study sample
Table 2 shows the sample characteristics for 2598 partic-
ipants of the 8-year follow-up of the ESTHER study aged
on average about 70 years. 52 % of participants were
female, 73 % married, 17 % widowed, others divorced or
single. The majority of participants had a primary and
secondary school education of not more than 9 years.
Ninety-two percent were insured by a statutory health
insurance.
The frailty syndrome with population-independent
cut-points could be calculated for 2589 individuals, as
the weight loss could not be documented for 9 observa-
tions. For one individual, both the status of potential
weight loss and the symptom of physical activity were
missing. The remaining symptoms of exhaustion, slow-
ness and weakness were documented completely for all
participants. About one third of the sample was non-
frail. A majority of 58 % of participants had a score of ‘1’
or ‘2’ on the frailty index and was therefore classified as
pre-frail. The frailty syndrome was present in 8 % of par-
ticipants who scored at least 3 points. The prevalence of
slowness was highest among frailty symptoms, with
about 36 % being affected, followed by weakness (31 %)
and low physical activity (20 %). In contrast, exhaustion
occurred in only 12 % and weight loss in only 4 % of
participants.
Descriptive analyses
Table 3 shows the mean health care costs per respond-
ent for a 3-month period by health care sector and in
total. Mean total costs were €874 (SD: €2197), thereof
44 % inpatient costs, 31 % outpatient costs, and 19 %
costs of pharmaceuticals. Nursing care contributed only
5 % to total costs. An increasing frailty index score was
associated with increased costs in all health care sectors
as well as total costs. In particular, costs of inpatient care
increased substantially with the frailty index score,
amounting to €2104 in frail participants with an index ≥4
compared to €268 in non-frail participants. Non-frail par-
ticipants utilized almost no nursing care services, resulting
in mean costs of only €2 in this sector. In contrast, mean
costs of nursing care for frail participants amounted to
€262 (frailty index 3) or €672 (frailty index ≥4) in the con-
sidered 3 month period. Mean costs of pharmaceuticals
steadily increased with the frailty index score, ranging
from €128 (non-frail) to €400 (frailty index 4 or 5).
Regarding the five constituting symptoms of frailty,
mean costs always increased if one of the symptoms was
present. This applied to costs in all considered health
care sectors and to total costs. The increase in costs was
most pronounced for unintentional weight loss where
mean total costs of affected participants were €1630
higher compared to participants without this symptom.
Table 2 Sample characteristics (N = 2598)
Characteristic N %
Age in years Mean: 69.55 SD: 6.23
Sex - female 1339 51.5 %
- male 1259 48.5 %
Marital status - single 84 3.3 %
- married 1874 72.8 %
- divorced 177 6.9 %
- widowed 4,8 17.0 %
Education ≤9 years 1708 66.7 %
10–11 years 451 17.6 %
≥12 years 402 15.7 %
Type of health insurance - SHI 2375 92.1 %
- PHI 203 7.9 %
Frailty - Non-frail (0) 876 33.8 %
- Pre-frail (1) 1034 39.9 %
- Pre-frail (2) 472 18.2 %
- Frail (3) 142 5.5 %
- Frail (4) 61 2.4 %
- Frail (5) 4 0.2 %
Low physical activity no 2078 80.0 %
yes 520 20.0 %
Exhaustion no 2290 88.1 %
yes 308 11.9 %
Weight loss no 2479 95.8 %
yes 110 4.2 %
Slowness no 1665 64.1 %
yes 933 35.9 %
Weakness no 1788 68.8 %
yes 810 31.2 %
SD Standard deviation, PHI Private Health Insurance,
SHI Statutory Health Insurance
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This difference was mainly due to inpatient costs which
differed by about €1400.
Inferential analyses of frailty index
Table 4 shows the results of the multivariate regression
models for total and sectoral 3-month costs per respond-
ent as dependent variable, with frailty as main independ-
ent variable, presenting the marginal effects at means of
all variables. All regressions models were estimated (1)
without and (2) with controlling for comorbidity.
In the models without controlling for comorbidity (1),
a frailty index ≥4 was statistically significantly associated
with total costs (+€3094; p < .001) as well as with all sec-
toral health care costs. None of the other covariates was
significantly associated with total costs. In particular, age
was not associated with higher total costs when control-
ling for frailty, whereas age was strongly associated with
total costs when the variable ‘frailty’ was removed from
the regression model (model not shown here). Besides
frailty, age was significantly associated with higher costs
for nursing care, while being divorced was significantly
associated with lower costs for nursing care.
In the models controlling for comorbidity (2), frailty was
still associated with higher total costs. However,
corresponding marginal effects were generally lower com-
pared to the model without comorbidity. In the outpatient
and the nursing care sector, there was no significant asso-
ciation between frailty and costs. In contrast, frailty index
scores of 2, 3 or ≥4 were significantly associated with
increased costs for pharmaceuticals. A frailty index ≥4 in-
creased inpatient costs by about €1279. In all health care
sector as well as in total, comorbidity was associated with
increased costs.
Inferential analyses of frailty symptoms
Table 5 shows the results of multiple regression analyses,
but unlike Table 4, with the individual symptoms of
frailty as the main independent variables instead of the
frailty status.
Without controlling for comorbidity (1), there was a sta-
tistically significant association between each single symp-
tom of frailty and total costs except for ‘slowness’ and
‘weakness’. Among the three symptoms, unintentional
weight loss was most strongly associated with total costs
with higher total costs of €1329 (p < .01) compared to no
weight loss. The symptom of exhaustion had the second
highest on total costs (+€816; p < .001) followed by low
physical activity (+€302; p < 0.01). With respect to
Table 3 Mean 3-month health care costs in € (2009 Values) by frailty status
Frailty-Index N Total (SD) Outpatient (SD) Inpatient (SD) Nursing care (SD) Pharmaceuticals (SD)
Non-frail (0) 876 642 (1546) 243 (500) 268 (1362) 2 (35) 128 (218)
Pre-frail (1) 1034 733 (1628) 281 (567) 286 (1396) 11 (196) 154 (278)
Pre-frail (2) 472 1014 (2322) 270 (380) 492 (2149) 30 (342) 221 (286)
Frail (3) 142 1616 (4002) 345 (718) 747 (3082) 262 (1237) 263 (246)
Frail (4&5) 65 3659 (5918) 483 (777) 2104 (5268) 672 (1894) 400 (679)
Low physical activity
- yes 520 1283 (2919) 291 (526) 575 (2524) 151 (874) 266 (397)
- no 2078 771 (1963) 270 (534) 341 (1676) 15 (288) 145 (238)
Exhaustion
- yes 308 1853 (4189) 367 (503) 990 (3520) 232 (1160) 265 (406)
- no 2290 742 (1725) 263 (263) 307 (1512) 16 (256) 156 (258)
Weight loss
- yes 110 2435 (4254) 377 (639) 1762 (3969) 39 (257) 256 (574)
- no 2479 805 (2036) 270 (527) 328 (1708) 42 (479) 166 (261)
Slowness
- yes 933 1099 (2815) 282 (488) 509 (2390) 103 (761) 206 (293)
- no 1665 747 (1746) 271 (556) 320 (1515) 7 (137) 149 (273)
Weakness
- yes 810 1063 (2834) 315 (671) 474 (2320) 93 (755) 180 (283)
- no 1788 788 (1831) 257 (456) 349 (1639) 18 (250) 164 (279)
All 2598 874 (2197) 275 (532) 388 (1878) 42 (471) 169 (282)
SD Standard deviation
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inpatient costs, besides the effect of unintentional weight
loss, only exhaustion had a statistically significant positive
effect. In the outpatient sector, exhaustion and weakness
were statistically significantly associated with costs. For
nursing care only ‘low activity’ was statistically signifi-
cantly associated with costs.
When controlling for comorbidity (2), the marginal ef-
fects of frailty symptoms generally decreased as compared
to the previous models. Yet ‘exhaustion’ and ‘weight loss’
were still significantly associated with total costs and in-
patient costs. The associations of ‘low activity’, ‘exhaustion’
and ‘slowness’ with pharmaceutical costs found in models
(1) persisted in models (2) with their estimated marginal
effect being somewhat decreased.
Sensitivity analyses
We ran Tobit regression models analogous to the glms
in Table 4 and 5 in order to test for the robustness of
the results. The Tobit models, in general, confirmed the
results of the glms. All marginal effects related to frailty
that reached the level of significance in the glms did so
in the Tobit models. In the Tobit model controlling for
comorbidity, frailty index scores of 3 and ≥4 were sig-
nificantly associated with total costs, with marginal
effects of €784 and €2601, respectively. Of the single
symptoms of frailty, exhaustion and weight loss were
positively associated with total costs when controlling
for comorbidity in the Tobit models. In addition, the as-
sociation of low activity and total costs that was shown
Table 4 Multiple regression analysesa with health care costs as dependent variable and frailty status as main predictor variable
Models without comorbidity (1) Models with comorbidity (2)
Total Inpatientb Outpatient Pharmaceuticals Nursing
careb
Total Inpatientb Outpatient Pharmaceuticals Nursing
careb
Prefrail (1) 77.51 2.94 35.15 26.76 12.74 56.19 −10.18 33.15 17.57 10.14
(73.88) (63.68) (23.38) (10.95)* (10.35) (73.21) (63.21) (23.25) (9.72) (9.06)
Prefrail (2) 366.93 245.08 25.23 95.81 8.31 227.08 169.58 9.93 62.03 5.40
(124.28)** (125.43) (29.65) (19.11)*** (5.86) (111.61)* (112.66) (28.71) (15.34)*** (4.81)
Frail (3) 968.14 515.10 100.01 143.38 76.96 680.42 368.85 55.84 87.31 48.97
(330.26)** (261.58)* (61.57) (40.15)*** (47.75) (273.12)* (219.89) (54.52) (29.41)** (33.38)
Frail (4 & 5) 3093.56 1946.88 234.64 303.25 334.93 1917.03 1278.81 161.10 123.96 181.00
(1119.22)** (847.00)* (118.79)* (95.03)** (167.83)* (772.18)* (623.41)* (101.48) (50.99)* (109.49)
Age 4.41 −0.50 1.07 1.20 1.02 1.12 −2.48 0.63 0.97 0.82
(6.41) (5.74) (1.77) (0.94) (0.50)* (6.07) (5.43) (1.73) (0.81) (0.43)
Sex 97.37 94.22 −22.32 24.34 3.08 25.51 56.32 −33.31 14.75 0.81
(80.06) (70.36) (22.68) (11.70)* (5.17) (74.73) (66.00) (22.17) (9.83) (4.36)
Single −156.63 −42.12 −21.16 −21.51 1.01 −214.93 −77.50 −40.70 −40.24 −2.39
(169.62) (140.52) (56.23) (27.99) (12.76) (145.24) (117.21) (50.60) (20.24)* (8.72)
Divorced 120.59 102.07 −24.30 −7.93 −12.42 139.17 100.90 −22.10 −0.56 −10.79
(172.23) (145.20) (39.22) (21.62) (5.12)* (166.91) (138.69) (38.66) (19.11) (4.79)*
Widowed 28.50 66.15 6.63 −18.00 −4.55 13.45 53.71 −0.52 −18.47 −4.71
(109.65) (98.89) (30.88) (14.49) (5.06) (101.63) (91.39) (29.59) (12.15) (4.36)
Education: 7.73 −46.47 56.69 3.99 5.39 39.37 −33.93 62.43 9.68 4.94
- middle (103.11) (87.39) (32.01) (15.23) (8.33) (99.17) (83.14) (31.46)* (13.13) (7.37)
- high −98.13 −73.63 −12.96 −26.15 −1.37 −73.33 −55.10 −12.03 −24.37 −0.47
(101.48) (92.30) (29.50) (14.25) (5.66) (96.79) (89.59) (28.53) (11.88)* (5.09)
Private HI 312.74 213.40 46.41 64.25 −7.67 348.30 219.27 54.34 78.70 −5.79
(191.36) (175.75) (47.08) (27.70)* (4.25) (188.13) (170.07) (46.77) (25.17)** (4.10)
Comorbidity ./. ./. ./. ./. ./. 46.69 19.52 8.07 10.45 0.71
(CIRS-G) ./. ./. ./. ./. ./. (7.79)*** (5.61)*** (2.06)*** (1.00)*** (0.32)*
N 2508 2508 2508 2508 2508 2508 2508 2508 2508 2508
CIRS-G Cumulative Illness Rating Scale for Geriatrics
* p < .05 **p < .01 *** p < .001
aMarginal effects of all variables at their means are reported; predictions obtained from generalized linear models with log link and gamma distribution or from
two part models when indicated. bpredictions obtained from two-part models with logit regression for the first part and log-gamma model for the second part
Bock et al. BMC Health Services Research  (2016) 16:128 Page 7 of 11
in the glm only without controlling for comorbidity,
remained in Tobit model after controlling for comorbid-
ity in the (p < .01).
Discussion
This study analyzed the relationship between frailty
and health care costs in a cross-sectional design of a
population-based sample of community-dwelling older
Germans. Frailty was operationalized by the five criteria
suggested by Fried et al. (weakness, slowness, exhaustion,
unintentional weight loss, and physical inactivity), using
population-independent cut-off-points.
Frailty was strongly associated with total health care
costs with this association persisting in regression models
that additionally controlled for comorbidity. In particular,
the frailty index was associated with inpatient costs and
pharmaceutical costs, with the latter association also per-
sisting after controlling for comorbidity. An observed
strong significant association between age and total health
care costs did not persist when controlling for frailty.
Among the five symptoms of frailty, the presence of low
Table 5 Multiple regression analysesa with health care costs as dependent variable and symptoms of frailty as main predictor variable
Models without comorbidity (1) Models with comorbidity (2)
Total Inpatientb Outpatient Pharmaceuticals Nursing
careb
Total Inpatientb Outpatient Pharmaceuticals Nursing
careb
Low activity 302.39 137.64 2.75 98.58 36.96 98.51 40.34 −19.28 65.29 28.00
(116.48)** (98.30) (27.06) (18.90)*** (17.99)* (96.52) (81.47) (25.26) (14.85)*** (15.07)
Exhaustion 816.48 457.81 83.66 73.89 42.65 664.33 391.67 66.72 44.05 30.23
(211.81)*** (165.88)** (40.50)* (22.85)** (27.19) (182.61)*** (148.53)** (37.68) (17.55)* (21.54)
Slowness 93.23 69.43 −2.88 39.67 12.61 53.73 52.22 −10.03 22.42 8.73
(83.15) (72.80) (22.44) (12.16)** (8.83) (76.38) (66.78) (21.50) (10.20)* (7.89)
Weakness 58.60 −11.61 50.72 1.20 0.12 23.83 −32.06 44.39 −1.22 0.23
(82.82) (66.30) (24.70)* (11.76) (4.09) (75.67) (60.47) (23.60) (10.01) (3.97)
Weight loss 1329.28 1331.25 97.01 62.17 0.73 1131.58 1150.01 86.13 27.72 −0.92
(471.93)** (432.21)** (68.77) (36.62) (7.08) (407.97)** (379.96)** (64.65) (26.77) (5.13)
Age 4.28 −0.2 1.23 1.64 0.48 1.75 −2.02 0.82 1.22 0.40
(6.25) (5.53) (1.76) (0.92) (0.34) (5.84) (5.17) (1.71) (0.80) (0.30)
Sex 82.40 77.15 −17.43 21.64 3.31 0.36 37.21 −30.00 13.93 1.64
(78.23) (67.21) (22.73) (11.37) (4.43) (72.23) (62.45) (22.06) (9.76) (3.83)
Single −132.22 −64.76 −10.93 −17.39 −0.55 −193.27 −93.65 −33.02 −37.61 −2.46
(169.48) (122.03) (57.84) (27.5) (8.72) (142.33) (100.29) (51.44) (20.22) (6.05)
Divorced 104.08 103.67 −28.22 −5.42 −7.04 117.11 107.55 −25.62 0.67 −6.37
(162.86) (138.62) (38.3) (21.08) (3.99) (154.80) (132.55) (37.55) (18.91) (3.86)
Widowed 26.50 53.21 7.63 −15.41 −3.82 4.50 38.67 −0.91 −17.14 −3.83
(105.49) (92.05) (30.69) (14.11) (3.23) (95.45) (83.17) (29.11) (12.03) (2.94)
Education: 7.20 −20.47 55.23 5.82 −0.13 34.29 −4.07 60.28 9.93 0.38
- middle (99.37) (84.79) (31.70) (14.75) (4.49) (93.83) (80.71) (30.86) (12.94) (4.33)
- high −90.79 −39.58 −16.81 −20.38 3.93 −62.48 −23.18 −16.03 −21.01 4.06
(99.65) (91.88) (29.16) (14.11) (7.46) (94.06) (87.48) (27.98) (11.97) (7.02)
Private HI 373.25 237.29 45.97 65.01 −4.22 393.33 242.59 54.18 77.74 −3.12
(195.27) (177.47) (46.66) (26.87)* (3.83) (187.09)* (170.37) (46.03) (24.72)** (3.94)
Comorb. ./. ./. ./. ./. ./. 47.34 19.45 8.31 10 0.51
(CIRS-G) ./. ./. ./. ./. ./. (7.49)*** (5.41)*** (2.03)*** (0.98)*** (0.28)
N 2508 2508 2508 2508 2508 2508 2508 2508 2508 2508
CIRS-G Cumulative Illness Rating Scale for Geriatrics
* p < .05 **p < .01 *** p < .001
aMarginal effects of all variables at their means are reported predictions obtained from generalized linear models with log link and gamma distribution or from
two part models when indicated. bpredictions obtained from two-part models with logit regression for the first part and log-gamma model for the second part
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activity, exhaustion, and weight loss were associated with
higher total costs, with unintentional weight loss and ex-
haustion having the greatest effects even after controlling
for comorbidity.
Except for Hastings et al., who found no association be-
tween frailty and health care utilization in the outpatient
sector [15], most previous studies generally suggested a
positive association between frailty and health care
utilization in all health care sectors [9, 16–19]. However,
as these studies mainly focused on ‘health care utilization’,
the relationship between frailty and corresponding costs
has rarely been examined. Thus, our study is in line with
the literature. It contributes to the literature by providing
further evidence on the association between frailty and
costs for a population-based larger sample. One recent
study [20] also investigated frailty and comprehensive
health care costs, but analyses were limited to a rather
small sample of 115 cognitively impaired older adults. For
this specific group, frailty was an important driver in par-
ticular of informal care costs, whereas the authors did not
find significant differences for frailty statuses in formal
health care costs.
Beyond that, Peters et al. [21] evaluated the predictive
validity of a frailty measure on health care costs. They
showed that frailty was a significant predictor of total
costs, and in particular long-term care costs. However,
frailty was not found to be a predictor of costs of “curative
care”, which included inpatient and outpatient physician
care and pharmaceuticals. In contrast to our cross-
sectional study, participants in Peters et al. were older (on
average 80 years vs. 70 years), and much more often insti-
tutionalized (36 % vs. less than 1 %). In our study, frailty
and nursing care costs were not significantly associated
after controlling for comorbidity probably due to the small
proportion of nursing care costs with high variance (on
average €42 ± €471 for a 3-month period). Besides, meas-
ure of frailty in Peters et al. (Groningen Frailty Indicator,
GFI) differed from our study, with the GFI being self-
assessed and already including aspects of comorbidity and
psychosocial as well as cognitive dimensions.
Beyond the costing studies cited above, our study adds
insights into the relationship of single frailty symptoms
and health care costs. Table 5 shows that each frailty
symptom contributes to sectoral and total costs differ-
ently. While the relationship among the frailty symptoms
has been examined [56], their association with costs was
unclear. Our results underline that the term ‘frailty’ covers
a heterogeneous group with each symptom having a spe-
cific relation towards sectoral and total costs.
A limiting factor of our study was that data on health
service utilization were self-reported by participants;
therefore recall bias cannot not be ruled out. In addition,
although not excluded from participation in the ESTHER
study, there were only two participants living in nursing
homes and three participants living in assisted living facil-
ities, limiting the representativeness of the study and im-
peding any conclusions for institutionalized persons.
Participants were only included when agreeing to pass the
geriatric assessments. Thus, effects of sample selection
might have influenced cost estimates. This might espe-
cially be the case for persons suffering from a high level of
multimorbidity or frailty who potentially refrained from
participating. Thus, cost estimates of frailty in this study
are likely to be rather conservative, which is, for instance,
indicated by the low number of participants with a frailty
index of 5, or the mean age of about 70 years without con-
sidering age brackets older than 84. A particular strength
of our study was the use of population-independent cut
points so that the prevalence of frailty did not rely on the
specific sample, facilitating comparison with other studies.
Participants of our sample were slightly more often
married than people of comparable age from the entire
German population: 74 % vs. about 66 % [57]. The edu-
cational level, based on the same classification in three
groups that we used, could not be compared to the en-
tire population data, as it is not available. For the
remaining control variables (sex, age and type of health
insurance), there were only slight differences between
our sample and the entire population for the cohort
aged 57 to 84. This indicates broad representativeness of
the 8-year follow-up with regard to the considered
socio-economic characteristics. We did not include the
variable ‘income’ for two reasons: first, the idea of repre-
senting individual economic capacity is already partly
captured by the educational level and type of health in-
surance. Second, the collection in surveys is difficult,
leading to potential inaccuracy and missing values [58].
Conclusions
The study provides evidence that frailty is associated
with increased health care costs. The analyses further-
more indicate that frailty is an important factor inde-
pendent from pure age and comorbidity for analyzing
health care costs. Costs were rather attributable to frailty
(and comorbidity) than to age. This stresses that the
overlapping concepts of multimorbidity and frailty are
both necessary to explain health care use and corre-
sponding costs among older adults.
This study furthermore underlines the health economic
importance of frailty. The phenomenon of frailty will
certainly require more attention in the aging societies of
industrialized countries and be a major task for their
health care systems.
Future research should further analyze the relationship
of frailty and costs by using broader definitions of frailty
that include e.g. emotional dimensions. Beyond that,
future studies based on panel data should examine the
Bock et al. BMC Health Services Research  (2016) 16:128 Page 9 of 11
longitudinal relationship between frailty, comorbidity
and health care costs.
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